Claimont Pharma Ltd
Registered number: 12588838
Balance Sheet
as at 30 June 2023
Notes 2023 2022
£ £
Current assets
Debtors 3 14,898 202
Cash at bank and in hand 8,742 8,591
23,640 8,793
Creditors: amounts falling due within one year 4 (99,826) (93,978)
Net current liabilities (76,186) (85,185)
Total assets less current liabilities (76,186) (85,185)
Net liabilities (76,186) (85,185)
Capital and reserves
Called up share capital 10 10
Profit and loss account (76,196) (85,195)
Shareholder's funds (76,186) (85,185)
The director is satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The member has not required the company to obtain an audit in accordance with section 476 of the Act.
The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Dr V Gradillas Gonzalez
Director
Approved by the board on 28 February 2024
Claimont Pharma Ltd
Notes to the Accounts
for the year ended 30 June 2023
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Going Concern
At 30 June 2023, the company had net current liabilities of £76,186 (2022: £85,185). The company is funded by intercompany loans from its fellow subsidiaries. As a result of this ongoing support, the directors consider the going concern basis appropriate for the Company.
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
2 Employees 2023 2022
Number Number
Average number of persons employed by the company - -
3 Debtors 2023 2022
£ £
Amounts owed by group undertakings and undertakings in which the company has a participating interest 10 10
Other debtors 14,888 192
14,898 202
Amounts owed by group undertakings are unsecured, interest free and repayable on demand.
4 Creditors: amounts falling due within one year 2023 2022
£ £
Trade creditors 235 83
Amounts owed to group undertakings and undertakings in which the company has a participating interest 94,816 93,096
Other creditors 4,775 799
99,826 93,978
Amounts owed to group undertakings are unsecured, interest free and repayable on demand.
5 Controlling party
The ultimate parent undertaking is Claimont Group Limited, a company registered in Jersey, which is controlled by Dr V Gradillas Gonzalez, a director of the company
6 Other information
Claimont Pharma Ltd is a private company limited by shares and incorporated in England. Its registered office is:
9 Park Place
Newdigate Road
Harefield
Middlesex
UB9 6EJ
Claimont Pharma Ltd 12588838 false 2022-07-01 2023-06-30 2023-06-30 VT Final Accounts October 2023 release 2 Dr V Gradillas Gonzalez No description of principal activity 12588838 2021-07-01 2022-06-30 12588838 core:WithinOneYear 2022-06-30 12588838 core:ShareCapital 2022-06-30 12588838 core:RetainedEarningsAccumulatedLosses 2022-06-30 12588838 2022-07-01 2023-06-30 12588838 bus:PrivateLimitedCompanyLtd 2022-07-01 2023-06-30 12588838 bus:AuditExemptWithAccountantsReport 2022-07-01 2023-06-30 12588838 bus:Director40 2022-07-01 2023-06-30 12588838 1 2022-07-01 2023-06-30 12588838 2 2022-07-01 2023-06-30 12588838 countries:England 2022-07-01 2023-06-30 12588838 bus:FRS102 2022-07-01 2023-06-30 12588838 bus:FullAccounts 2022-07-01 2023-06-30 12588838 2023-06-30 12588838 core:WithinOneYear 2023-06-30 12588838 core:ShareCapital 2023-06-30 12588838 core:RetainedEarningsAccumulatedLosses 2023-06-30 12588838 2022-06-30 iso4217:GBP xbrli:pure